OC
JUNO

Oppenheimer & Co’s Juno Therapeutics, Inc. JUNO Stock Holding History

Oppenheimer & Co’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-8,001
Closed -$485K – 1600
2015
Q1 		$485K Buy
+8,001
New +$388K 0.01% 880

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Oppenheimer & Co's JUNO Position: Q2 2015 in Review

Oppenheimer & Co sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2015, closing a stake of 8,001 shares — an estimated $485K sold.

Oppenheimer & Co first reported a position in JUNO in Q1 2015 and held it in 1 quarter. The position peaked at $485K in Q1 2015. 154 funds tracked by Wall St. Rank hold JUNO as of Q2 2015.

  • Oppenheimer & Co reported no remaining Juno Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Oppenheimer & Co sold 8,001 Juno Therapeutics, Inc. shares in Q2 2015, an estimated $485K.
  • Oppenheimer & Co first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Oppenheimer & Co's Juno Therapeutics, Inc. position peaked at $485K in Q1 2015.
  • 154 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2015.

Based on Oppenheimer & Co's 13F filing for Q2 2015, filed 12 Aug 2015.